Inpharma 1648 - 26 Jul 2008

■ Ziprasidone effectively improves QOL amongpatients with schizophrenia who are switched fromtypical and/or atypical antipsychotics, according toresearchers from Italy. A total of 312 patients withschizophrenia were switched from typical and/oratypical antipsychotic therapy to ziprasidone, due tointolerance or inadequate response. Patients receivedopen label ziprasidone 40–160 mg/day for 8 weeks.*At study end, significant improvements from baselinewere reported in mean Positive and NegativeSyndrome Scale scores, Global Assessment ofFunctioning, Clinical Global Impression Severity,Subjective Well-being scores, and Trail Making Test.* This study was sponsored by Pfizer Italia.

Rossi A, et al. Assessment of clinical and metabolic status, and subjectivewell-being, in schizophrenic patients switched from typical and atypicalantipsychotics to ziprasidone. International Clinical Psychopharmacology 23:216-222, No. 4, Jul 2008 801111890

1

Inpharma 26 Jul 2008 No. 16481173-8324/10/1648-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved